Cardiovascular risk factors and probability for cardiovascular events in HIV-infected patients: Part II: Gender differences

European Journal of Medical Research

Volumn 9, Issue 2, 2004, Pages 55-60

  Neumann, Till ^a   Woiwod, T ^a   Neumann, A ^a   Ross, B ^a   Von Birgelen, C ^a,b   Volbracht, L ^a   Brockmeyer, N ^c   Gerken, G ^a   Erbel, R ^a  

^a UNIVERSITY OF DUISBURG ESSEN   (Germany)

^b MEDISCH SPECTRUM TWENTE   (Netherlands)

^c RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

Arteriosclerosis; Cardiovascular risk factors; Gender; HIV

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTERIOSCLEROSIS; ARTICLE; BLOOD; CARDIOVASCULAR DISEASE; CLINICAL CHEMISTRY; FEMALE; GERMANY; GLUCOSE BLOOD LEVEL; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MALE; PATHOPHYSIOLOGY; RISK FACTOR; SEX DIFFERENCE;

ADULT; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ARTERIOSCLEROSIS; BLOOD GLUCOSE; CARDIOVASCULAR DISEASES; CHOLESTEROL; CLINICAL CHEMISTRY TESTS; FEMALE; GERMANY; HIV; HIV INFECTIONS; HUMANS; MALE; RISK FACTORS; SEX FACTORS; TRIGLYCERIDES;

EID: 5444264563     PISSN: 09492321     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Assmann G, Schulte H, von Eckardstein A (1996) Hypertriglyceridemia and elevated lipoprotein (a) are risk factors for major coronary events in middle-aged men. Am J Cardiol 77: 1179-1184
2. Behrens G, Dejam A, Schmidt H, Balks HJ, Brabant G, Korner T, Stoll M, Schmidt RE (1999) Impaired glucose tolerance and beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 13: F63-F70
3. Bozzette SA, Ake CF, Tam HK, Chang SW, Louis TA (2003) Cardiovascular and cerebrovascular events in patients treated for human immunodeficiency virus infection. N Engl J Med 34: 702-710
4. Carr A, Samaras K, Burton S, Law M, Freund J, Chisholm DJ, Cooper DA (1998) A syndrome of peripheral lipodystrophy, hyperlipidaemia, and insulin resistance in patients receiving HIV protease inhibitors. AIDS 12: F51-F58
5. Detels R, Munoz A, McFarlane G, Kingsley LA, Margolick JB, Giorgi J, Schrader LK, Phair JP (1998) Effectiveness of potent antiretroviral therapy on time to AIDS and death in men with known HIV infection duration. Multicenter AIDS Cohort Study Investigators. JAMA 280: 1497-1503
6. Detels R, Tarwater P, Phair JP, Margolick J, Riddler SA, Minoz A (2001) Effectiveness of potent antiretroviral therapies on the incidence of opportunistic infections before and after AIDS diagnosis. AIDS 15: 347-355
7. Fisher SD, Lipshultz SE (2001) Cardiovascular abnormalities in HIV-infected individuals. In: Braunwald E (ed) Heart disease: a text book of cardiovascular medicine. WB Saunders, Philadelphia, pp 2211-2221
8. Klein D, Hurley L, Quesenberry CP Jr, Sidney S (2002) Do protease inhibitors increase the risk for coronary heart disease in patients with HIV-1 infection? J Acquir Immune Defic Syndr 15: 471-477
9. Morgello S, Mahboob R, Yakoushina T, Khan S, Hague K (2002) Autopsy findings in a human immunodeficiency virus-infected population over 2 decades. Arch Pathol Lab Med 126: 182-190
10. Neumann T, Woiwoid T, Neumann A, Miller M, Ross B, Volbracht L, Brockmeyer N, Gerken G, Erbel R (2003) Cardiovascular risk factors and probability for cardiovascular events in HIV-infected patients: Part I: Differences due to the acquisiton of HIV-infection. Eur J Med Res 8: 229-235
11. Palella FJ Jr. Delaney KM, Moorman AC, Loveless MO, Fuhrer J, Satten GA, Aschman DJ, Holmberg SD (1998) Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 338: 853-860
12. Periard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ, Marcovina SM, Glauser MP, Nicod P, Darioli R, Mooser V (Swiss Cohort Study) (1999) Atherogenic dyslipidaemia in HIV-infected individuals treated with proteinase inhibitors. Circulation 100: 700-705
13. Statistisches Bundesamt (2001) Fragen zur Gesundheit. Metzler Poeschel, Stuttgart, 12,S3
14. Stein JH, Klein MA, Bellehumeur JL, McBride PE, Wiebe DA, Otvos JD, Sosman JM (2001) Use of human immunodeficiency virus-1 protease inhibitors is associated with aterogenic lipoprotein changes and endothelial dysfunction. Circulation 104: 257-262
15. Walli R, Herfort O, Michl GM, Demant T, Jager H, Dieterle C, Bogner JR, Landgraf R, Goebel FD (1998) Treatment with protease inhibitors associated with peripheral insulin resistance and impaired oral glucose tolerance in HIV-1 infected patients. AIDS 12: F167-F173
16. Wilson PWF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel WB (1998) Prediction of coronary heart disease using risk factor categories. Circulation 97: 1837-1847